Preclinical and First-in-Human Study of Carbonic Anhydrase IX–Targeting Theranostic Pair, [ 68 Ga]Ga/[ 177 Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma

Lu]Lu-NYM096 is feasible, offering a strategy for patients with end-stage ccRCC. The gastric toxicity proposes a significant challenge for CAIX-targeting radiopharmaceutical therapy.